©The Author(s) 2021.
World J Hepatol. Jan 27, 2022; 14(1): 244-259
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.244
Published online Jan 27, 2022. doi: 10.4254/wjh.v14.i1.244
Table 3 Summary of Response Evaluation Criteria in Solid Tumors response and chemotherapy regimes in response and non-response group
| Response group | Non-response group | |
| RECIST response | ||
| CR | 0 | |
| PR | 15 | |
| SD | 7 | |
| PD | 7 | |
| Chemotherapy regimen | ||
| FOLFOX | 4 | 4 |
| FOLFIRI | 4 | 3 |
| FOLFOXIRI | 2 | 0 |
| CAPE-OX | 2 | 3 |
| CAPE-IRI | 2 | 3 |
| Capecitabine | 1 | 1 |
| Number of chemotherapy cycles between baseline and follow-up scan | ||
| Range in cycles (median) | 3-12 (8) | 3-12 (6) |
| Time between baseline and follow-up scan | ||
| Range in d (median) | 72-203 (141) | 76-198(111) |
- Citation: Rabe E, Cioni D, Baglietto L, Fornili M, Gabelloni M, Neri E. Can the computed tomography texture analysis of colorectal liver metastases predict the response to first-line cytotoxic chemotherapy? World J Hepatol 2022; 14(1): 244-259
- URL: https://www.wjgnet.com/1948-5182/full/v14/i1/244.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i1.244